CVE:KNE

Kane Biotech Competitors

C$0.16
-0.01 (-5.88 %)
(As of 04/12/2021 03:51 PM ET)
Add
Compare
Today's Range
C$0.16
Now: C$0.16
C$0.17
50-Day Range
C$0.12
MA: C$0.15
C$0.18
52-Week Range
C$0.11
Now: C$0.16
C$0.21
Volume90,000 shs
Average Volume111,835 shs
Market CapitalizationC$17.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Kane Biotech (CVE:KNE) Vs. COV, EMH, IGX, QPT, CZO, and CTX

Should you be buying KNE stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Kane Biotech, including Covalon Technologies (COV), Emerald Health Therapeutics (EMH), IntelGenx Technologies (IGX), Quest PharmaTech (QPT), Ceapro (CZO), and Crescita Therapeutics (CTX).

Kane Biotech (CVE:KNE) and Covalon Technologies (CVE:COV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Profitability

This table compares Kane Biotech and Covalon Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kane BiotechN/AN/AN/A
Covalon TechnologiesN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Kane Biotech and Covalon Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kane Biotech0000N/A
Covalon Technologies0000N/A

Valuation & Earnings

This table compares Kane Biotech and Covalon Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kane BiotechC$1.34 million12.95C$-3,801,490.00C($0.04)-4.57
Covalon TechnologiesC$23.84 million1.53C$-6,144,922.00C($0.24)-5.92

Kane Biotech has higher earnings, but lower revenue than Covalon Technologies. Covalon Technologies is trading at a lower price-to-earnings ratio than Kane Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Kane Biotech beats Covalon Technologies on 4 of the 5 factors compared between the two stocks.

Emerald Health Therapeutics (CVE:EMH) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Emerald Health Therapeutics and Kane Biotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emerald Health Therapeutics0000N/A
Kane Biotech0000N/A

Profitability

This table compares Emerald Health Therapeutics and Kane Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emerald Health TherapeuticsN/AN/AN/A
Kane BiotechN/AN/AN/A

Valuation and Earnings

This table compares Emerald Health Therapeutics and Kane Biotech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emerald Health TherapeuticsC$13.02 million4.17C$-142,699,488.00C($0.70)-0.38
Kane BiotechC$1.34 million12.95C$-3,801,490.00C($0.04)-4.57

Kane Biotech has lower revenue, but higher earnings than Emerald Health Therapeutics. Kane Biotech is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Kane Biotech beats Emerald Health Therapeutics on 3 of the 5 factors compared between the two stocks.

IntelGenx Technologies (CVE:IGX) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for IntelGenx Technologies and Kane Biotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IntelGenx Technologies0000N/A
Kane Biotech0000N/A

Valuation and Earnings

This table compares IntelGenx Technologies and Kane Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.54 million47.84C$-7,274,150.00C($0.07)-10.15
Kane BiotechC$1.34 million12.95C$-3,801,490.00C($0.04)-4.57

Kane Biotech has lower revenue, but higher earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Kane Biotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IntelGenx Technologies and Kane Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IntelGenx TechnologiesN/AN/AN/A
Kane BiotechN/AN/AN/A

Summary

Kane Biotech beats IntelGenx Technologies on 3 of the 5 factors compared between the two stocks.

Quest PharmaTech (CVE:QPT) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares Quest PharmaTech and Kane Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest PharmaTechN/AN/AN/A
Kane BiotechN/AN/AN/A

Valuation and Earnings

This table compares Quest PharmaTech and Kane Biotech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest PharmaTechC$38,871.00474.71C$109.88 millionC$0.660.17
Kane BiotechC$1.34 million12.95C$-3,801,490.00C($0.04)-4.57

Quest PharmaTech has higher earnings, but lower revenue than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Quest PharmaTech and Kane Biotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest PharmaTech0000N/A
Kane Biotech0000N/A

Summary

Quest PharmaTech beats Kane Biotech on 4 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Ceapro and Kane Biotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ceapro0000N/A
Kane Biotech0000N/A

Valuation & Earnings

This table compares Ceapro and Kane Biotech's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CeaproC$16.14 million3.80C$2.56 millionC$0.0323.94
Kane BiotechC$1.34 million12.95C$-3,801,490.00C($0.04)-4.57

Ceapro has higher revenue and earnings than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ceapro and Kane Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CeaproN/AN/AN/A
Kane BiotechN/AN/AN/A

Summary

Ceapro beats Kane Biotech on 4 of the 5 factors compared between the two stocks.

Crescita Therapeutics (TSE:CTX) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Crescita Therapeutics and Kane Biotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crescita Therapeutics0000N/A
Kane Biotech0000N/A

Profitability

This table compares Crescita Therapeutics and Kane Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crescita TherapeuticsN/AN/AN/A
Kane BiotechN/AN/AN/A

Valuation and Earnings

This table compares Crescita Therapeutics and Kane Biotech's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$15.64 million1.12C$41,296.00C$0.00425.00
Kane BiotechC$1.34 million12.95C$-3,801,490.00C($0.04)-4.57

Crescita Therapeutics has higher revenue and earnings than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Crescita Therapeutics beats Kane Biotech on 4 of the 5 factors compared between the two stocks.


Kane Biotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
COV
Covalon Technologies
0.6$1.41-0.7%C$37.44 millionC$23.84 million-5.92
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.27-9.4%C$34.02 millionC$13.02 million-0.38
IGX
IntelGenx Technologies
0.9$0.66-13.6%C$30.87 millionC$1.54 million-10.15High Trading Volume
News Coverage
QPT
Quest PharmaTech
0.8$0.11-0.0%C$21.76 millionC$38,871.000.17High Trading Volume
Gap Down
CZO
Ceapro
0.6$0.79-8.9%C$21.65 millionC$16.14 million23.94
CTX
Crescita Therapeutics
0.6$0.85-1.2%C$17.55 millionC$15.64 million425.00
GSD
Devonian Health Group
0.5$0.27-3.7%C$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09-5.6%C$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06-0.0%C$11.06 millionC$2.03 million-1.40Gap Down
MPH
Medicure
0.7$1.60-0.0%C$10.80 millionC$12.71 million-1.03Gap Up
BTI
Bioasis Technologies
0.7$0.44-11.4%C$10.16 millionC$4.12 million40.00
HEM
Hemostemix
0.6$0.48-2.1%C$9.07 millionN/A-2.86
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.36-1.4%C$6.94 millionC$5.60 million6.67
IOT
Innovotech
0.8$0.15-3.3%C$6.52 millionC$1.04 million75.00
BCT
BriaCell Therapeutics
0.5$4.90-30.6%C$4.48 millionN/A-1.58High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5$2.95-2.7%C$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.20
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49-6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32-5.3%C$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.